Expert Review of Anticancer Therapy最新文献

Role of locoregional therapy including liver transplantation in liver-only metastatic colorectal cancer: a review paper.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-01-05 DOI: 10.1080/14737140.2024.2447360

Laura Depauw, Amanda Townsend, Christos Karapetis, Amitesh Roy, Alan Wigg, Niall C Tebbutt, John Chen, Mark Brooke-Smith, Timothy Price

{"title":"Role of locoregional therapy including liver transplantation in liver-only metastatic colorectal cancer: a review paper.","authors":"Laura Depauw, Amanda Townsend, Christos Karapetis, Amitesh Roy, Alan Wigg, Niall C Tebbutt, John Chen, Mark Brooke-Smith, Timothy Price","doi":"10.1080/14737140.2024.2447360","DOIUrl":"10.1080/14737140.2024.2447360","url":null,"abstract":"Introduction: Resection of primary tumor and liver metastases is the gold standard for colorectal cancer with liver-only metastases (CRLM). Although treatment options have expanded to enable conversion of unresectable to resectable CRLM, about 40% of patients will have definitively unresectable disease. Major advances in surgical techniques, immunosuppressive protocols and patient selection criteria for liver transplantation have resulted in improved outcomes.Areas covered: A literature search has been conducted in Pubmed for articles published between 2014 and 2024. This review paper comments on current liver-directed treatment options for CRLM: resection, percutaneous ablation, conversion-chemotherapy, TACE, SIRT, and SABR. We explore evidence for liver transplantation in patients with unresectable CRLM, comment on possible limitations for implementation in clinical practice and give an overview of the current guidelines on liver transplantation in the USA, Europe, the United Kingdom, and Australia/New Zealand.Expert opinion: The recent randomized TRANSMET trial, investigating liver transplantation versus chemotherapy in unresectable CRLM, shows promising 5-year OS reaching similar values as for other accepted liver transplantation indications. Further investigations with RCTs to investigate reproducibility and feasibility in clinical practice are needed. Before liver transplantation can be implemented as a standard treatment option, reorganizations at federal, regional and hospital levels would be required.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-13"},"PeriodicalIF":2.9,"publicationDate":"2025-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Venetoclax and beyond: New Horizons in CLL and AML therapy.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-01-04 DOI: 10.1080/14737140.2025.2449944

Matteo Molica, Salvatore Perrone

引用次数: 0

Targeting PGE2-IL-1β axis to impact future treatments for pancreatic ductal adenocarcinoma and its precursors.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-01-03 DOI: 10.1080/14737140.2025.2450235

Paolo Riccardo Camisa, Nicoletta Caronni, Stefano Crippa

引用次数: 0

Practical insights into bispecific antibody therapy in multiple myeloma.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-27 DOI: 10.1080/14737140.2024.2445145

Yumena Kawasaki, Sara Winger, Naseem Esteghamat, Aaron Rosenberg, Ryan Beechinor

{"title":"Practical insights into bispecific antibody therapy in multiple myeloma.","authors":"Yumena Kawasaki, Sara Winger, Naseem Esteghamat, Aaron Rosenberg, Ryan Beechinor","doi":"10.1080/14737140.2024.2445145","DOIUrl":"https://doi.org/10.1080/14737140.2024.2445145","url":null,"abstract":"Introduction: The rise of recent novel therapies teclistamab, elranatamab, and talquetamab for the treatment of relapsed/refractory multiple myeloma (RRMM) is a rapidly evolving area with significant clinical implications that require exploration and evaluation.Areas covered: The current review highlights the clinical trial data, safety endpoints, and practical administration considerations for the bispecific therapies currently used in multiple myeloma. This article reviewed the efficacy and safety results between the three different bispecifics, and the differences in dosing and monitoring requirements. Adverse event management for the bispecific antibodies will be explored including the need for antimicrobial prophylaxis, premedication, and IVIG replacement. Future considerations for widespread bispecific administration and ongoing clinical trials are discussed.Expert opinion: Practical considerations for bispecific administration such as hospitalization requirements, monitoring of adverse events, and medication considerations are emphasized. Future directions and clinical implications regarding the pivotal role of these agents will be discussed.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-25 DOI: 10.1080/14737140.2024.2445152

Riccardo Serra, Emilio Francesco Giunta, Giuseppe Schepisi, Nicole Brighi, Daniela Montanari, Cristian Lolli, Sara Bleve, Margherita Piras, Giuseppe Palmieri, Mario Scartozzi, Panagiotis Paliogiannis, Ugo De Giorgi

{"title":"An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.","authors":"Riccardo Serra, Emilio Francesco Giunta, Giuseppe Schepisi, Nicole Brighi, Daniela Montanari, Cristian Lolli, Sara Bleve, Margherita Piras, Giuseppe Palmieri, Mario Scartozzi, Panagiotis Paliogiannis, Ugo De Giorgi","doi":"10.1080/14737140.2024.2445152","DOIUrl":"10.1080/14737140.2024.2445152","url":null,"abstract":"Introduction: Prostate cancer (PCa) is the second most common cancer diagnosis among men worldwide, with poor prognosis in its advanced stage. Treatment strategies have evolved, including the use of androgen receptor pathway inhibitors (ARPIs) and poly (ADP-ribose) polymerase inhibitors (PARPis).Areas covered: This review evaluates the clinical efficacy, safety, and future potential of combining talazoparib, a potent PARPi, with enzalutamide, a strong androgen receptor (AR) antagonist. The combination of these two drugs was evaluated by the TALAPRO-2 trial, demonstrating significant improvement in radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) patients, particularly those with Homologous Recombination Repair (HRR) gene mutations such as BRCA1/2.Expert opinion: Emerging biomarkers like TMPRSS2-ERG and RB1 gene mutations have been recently reported as potential predictors of clinical outcome in the TALAPRO-2 all-comers population. Genomic markers for homologous recombination deficiency (HRD) are other potential drivers of response to PARPi/ARPI combination. Further investigation is needed to refine treatment strategies, including targeting non-HRR mutations, and to expand the role of this combination therapy in earlier stages of prostate cancer.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.9,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The clinical potential of mechanistic models of individualized radiosensitivity.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-23 DOI: 10.1080/14737140.2024.2444385

Shannon J Thompson, Stephen J McMahon

引用次数: 0

Emerging therapeutics in the management of tenosynovial giant cell tumor (TGCT).

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-22 DOI: 10.1080/14737140.2024.2445754

Victoria Wytiaz, Geoffrey Siegel, Rashmi Chugh

{"title":"Emerging therapeutics in the management of tenosynovial giant cell tumor (TGCT).","authors":"Victoria Wytiaz, Geoffrey Siegel, Rashmi Chugh","doi":"10.1080/14737140.2024.2445754","DOIUrl":"10.1080/14737140.2024.2445754","url":null,"abstract":"Introduction: Tenosynovial giant cell tumors (TGCTs) are locally aggressive mesenchymal neoplasms that often occur in younger patients and cause long-term disability. Surgical management remains the standard of care, but with high risks of surgical morbidity, systemic treatment options are important to consider, particularly in diffuse disease. Improved understanding of the molecular pathogenesis of TGCTs has led to exciting developments in this arena.Areas covered: This review aims to provide historical context for systemic treatments for patients with TGCTs with a focus on the diffuse subtype (DT-TGCT) while exploring the more recently available treatments in depth. Current literature on TGCTs and therapy was reviewed and summarized by a comprehensive search of MEDLINE (1/1/1989-11/30/2024). We also suggest directions for future investigation in the systemic treatment space for TGCT with a goal to alleviate symptoms and improve quality of life while minimizing treatment-related toxicity.Expert opinion: Advances in the understanding of the molecular pathogenesis of TGCT has led to systemic therapies targeting the CSF1 receptor (CSF1R), including the first FDA approval in this space of pexidartinib. These developments provide the foundation for further investigation into additional treatments, optimal sequencing, and duration of therapies for patients with symptoms and reduced functionality secondary to TGCT.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.9,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic patterns and outcomes in older patients (aged≥65 years) with stage III-IVB inoperable oral cavity squamous cell carcinoma (OCSCC): an investigational study from the SEER database.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-20 DOI: 10.1080/14737140.2024.2441872

Wangyan Zhong, Hang Yuan, Ting Li, Jiwei Mao, Xueying Jin, Dongping Wu

{"title":"Therapeutic patterns and outcomes in older patients (aged≥65 years) with stage III-IVB inoperable oral cavity squamous cell carcinoma (OCSCC): an investigational study from the SEER database.","authors":"Wangyan Zhong, Hang Yuan, Ting Li, Jiwei Mao, Xueying Jin, Dongping Wu","doi":"10.1080/14737140.2024.2441872","DOIUrl":"10.1080/14737140.2024.2441872","url":null,"abstract":"Background: The aim of this retrospective study is to explore therapeutic patterns and survival outcomes for a cohort of older patients with stage III-IVB inoperable oral squamous cell carcinoma (OCSCC) patients receiving radiation therapy (RT) with or without chemotherapy (CT).Methods: This study conducted a retrospective review of 316 patients ≥ 65 aged years with stage III-IVB OCSCC from the Surveillance, Epidemiology, and End Results (SEER) registry (2010-2015). It compared RT alone (n = 109) with RT+CT (n = 207), utilizing Kaplan-Meier and Log-rank tests.Results: The estimated overall survival (OS) and cancer-specific survival (CSS) rates at 3 years were 20.6% and 25.9%, respectively. Both univariate and multivariate analyses identified that age and treatment option as independent prognosticators of OS and CSS. Further subgroup analyses showed that the combination of RT and CT significantly improved OS for all OCSCC patients, except those with hard palate tumors. Moreover, this combined treatment approach was linked to enhanced CSS in patients with gingival and tongue squamous cell carcinoma.Conclusion: RT+CT significantly enhanced survival in elderly OCSCC patients, particularly those with gingival and tongue cancers, but not in those with hard palate tumors.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.9,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142834832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-19 DOI: 10.1080/14737140.2024.2443009

Gozde Kavgaci, Taha Koray Sahin, Tugcenur Muderrisoglu, Serez Ileri, Deniz Can Guven, Sercan Aksoy

{"title":"Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer.","authors":"Gozde Kavgaci, Taha Koray Sahin, Tugcenur Muderrisoglu, Serez Ileri, Deniz Can Guven, Sercan Aksoy","doi":"10.1080/14737140.2024.2443009","DOIUrl":"10.1080/14737140.2024.2443009","url":null,"abstract":"Background: The prognostic role of preoperative carcinoembryonic antigen (CEA) in breast cancer is recognized, but the impact of postoperative CEA levels on survival in early breast cancer is uncertain.Research design and methods: We conducted a retrospective study of 921 non-metastatic breast cancer patients treated at anonymized. Patients were categorized as normal (CEA ≤3 µg/L) or elevated (CEA >3 µg/L).Results: Elevated postoperative CEA levels were associated with shorter disease-free survival (DFS) (median, 174.6 vs. 239.8 months; hazard ratio (HR): 1.80; 95% confidence interval (CI): 1.27-2.56; p < 0.001) and overall survival (OS) (median, 174.6 vs. 261.1 months; HR:2.34; 95% CI: 1.59-3.45; p < 0.001). Elevated CEA was associated with shorter DFS (median, 174.6 months vs. not reached (NR); HR:2.30; 95% CI: 1.03-5.19; p = 0.043) and OS (NR vs. NR; HR: 2.81; 95% CI: 1.06-7.48; p = 0.039) in stage 1, shorter DFS (median, 239. 8 vs. 141.1 months; HR: 1.95; 95% CI: 1.28-2.98; p = 0.002) and OS (median, 169 vs. 261.1 months; HR: 2.56; 95% CI: 1.6-4.12; p < 0.001) in stage 2 and shorter OS (median, 65 vs. 183.1 months; HR: 3.25; 95% CI: 1.19-8.83; p = 0.021) in stage 3.Conclusions: Elevated postoperative CEA indicates worse DFS and OS in patients with HR-positive/HER2-negative early breast cancer.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.9,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Activation of ferritin light chain (FTL) by transcription factor salmonella pathogenicity island 1 modulates glycolysis to drive metastasis of ovarian cancer cells.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-12-16 DOI: 10.1080/14737140.2024.2439558

Chunxiang Li, Yubin Yang, Yuting Lin, Yingbin Lian, Dinglong Pan, Lin Lin, Luhong Li

{"title":"Activation of ferritin light chain (FTL) by transcription factor salmonella pathogenicity island 1 modulates glycolysis to drive metastasis of ovarian cancer cells.","authors":"Chunxiang Li, Yubin Yang, Yuting Lin, Yingbin Lian, Dinglong Pan, Lin Lin, Luhong Li","doi":"10.1080/14737140.2024.2439558","DOIUrl":"10.1080/14737140.2024.2439558","url":null,"abstract":"Background: Ovarian cancer (OC) is the most lethal gynecological cancer often diagnosed at an advanced stage due to a lack of effective biomarkers. Ferritin light chain (FTL) is implicated in the development of various cancers, but its impact on OC remains unknown.Research design and methods: Bioinformatics methods were utilized to analyze FTL. Quantitative real-time polymerase chain reaction, western blot, and immunohistochemistry were employed for expression detection, and cell counting kit- 8, and transwell assays were for cell biological functions assessment. Extracellular acidification rate, oxygen consumption rate, and glycolytic metabolite contents were measured. Dual-luciferase and chromatin immunoprecipitation assay validated binding relationship. Xenografted tumor models in nude mice verified the role of FTL in vivo.Results: Cell function experiments revealed that FTL facilitated proliferation, migration, and invasion of OC cells. Rescue experiments unveiled that 2-Deoxy-D-glucose attenuated stimulation on OC cell metastasis and glycolysis by FTL overexpression. Salmonella pathogenicity island 1 (SPI1) up-regulated FTL expression to promote glycolysis and metastasis. FTL knockdown inhibited tumor growth and suppressed glycolysis and cell metastasis in vivo, while SPI1 overexpression attenuated these effects.Conclusions: This study demonstrated pro-metastatic mechanisms of transcription factor SPI1/FTL axis in OC and suggested it as a potential target for treating OC metastasis.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":2.9,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0